Veracyte to buy C2i Genomics for up to $95M, includes $70M upfront
08 Jan 2024
Acquisition
In announcing plans on Monday to pay up to $95 million for C2i Genomics, Veracyte is betting that it will expand further along the cancer care continuum.
The transaction involves $70 million upfront using Veracyte’s own shares, and up to an additional $25 million in milestone payments, payable in Veracyte shares or cash. The deal is expected to close in the first quarter.
Veracyte makes tests for guiding physicians in tough-to-treat diseases, including thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. By
acquiring C2I
, Veracyte can better monitor the success of a cancer therapeutic or surgical interventions.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.